# § 814.15   Research conducted outside the United States.

(a) *Data to support PMA.* If data from clinical investigations conducted outside the United States are submitted to support a PMA, the applicant shall comply with the provisions in § 812.28 of this chapter, as applicable.


(b) *As sole basis for marketing approval.* A PMA based solely on foreign clinical data and otherwise meeting the criteria for approval under this part may be approved if: 


(1) The foreign data are applicable to the U.S. population and U.S. medical practice; 


(2) The studies have been performed by clinical investigators of recognized competence; and 


(3) The data may be considered valid without the need for an on-site inspection by FDA or, if FDA considers such an inspection to be necessary, FDA can validate the data through an on-site inspection or other appropriate means. 


(c) *Consultation between FDA and applicants.* Applicants are encouraged to meet with FDA officials in a “presubmission” meeting when approval based solely on foreign data will be sought. 



---

[N] [51 FR 26364, July 22, 1986; 51 FR 40415, Nov. 7, 1986, as amended at 51 FR 43344, Dec. 2, 1986; 83 FR 7387, Feb. 21, 2018]




